Recruiting
Phase 2

Hemp-Derived Cannabinoids

Sponsor:

Washington State University

Code:

NCT07393672

Conditions

Menopause

Perimenopause

Eligibility Criteria

Sex: Female

Age: 40 - 60

Healthy Volunteers: Accepted

Interventions

Hemp-derived cannabinoids

Placebo

Study Details

Brief summary:

The purpose of the study is to examine the impact of hemp-derived minor cannabinoids on symptoms of menopause/perimenopause.

Conditions

Menopause

Perimenopause

Study ID

NCT07393672

Start date

Feb 11, 2026

Status verified date

Mar, 2026

Completion date

Nov 10, 2026

Anticipated

Primary completion date

Nov 10, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: Female

Age: 40 - 60

Healthy Volunteers: Accepted

Inclusion Criteria:

  • designated female at birth
  • 40-60 years of age
  • able to give informed consent (no intellectual disability)
  • stable pharmacotherapeutic regimen, no change in the past 3 months
  • abstinent from regular cannabis use (<1x/month) for past year, and willing to abstain from use for 3 months
  • abstinent for supplements, don't add any supplements (no changes in past 3 months)
  • own a smartphone
  • have access to Zoom on a secure, stable internet connection
  • perimenopausal or menopausal

Exclusion Criteria:

  • currently taking anti-depressant, anti-anxiety, and/or antipsychotic medication

  • severe depression, neurovegetative symptoms, or current suicidality
  • psychosis or family history of psychosis
  • pregnant or breastfeeding
  • chemotherapy
  • hypotension
  • drug testing for work or other reasons
  • illicit drug use in past 3 months (cannabis not illicit)
  • heavy alcohol use (4 drinks more than 4x/week)
  • international/air travel planned for more than one week in the next 3 months
  • cocounut allergy

Study Design

Enrollment

104 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Basic Science

Interventions and Outcome Measures

Arms

placebo comparator: Placebo Arm

Participants in this arm will receive a placebo.

active comparator: Active Arm

Participants in this arm will receive an active product.

Interventions

Hemp-derived cannabinoids

Participants will be administered a legal product with hemp-derived cannabinoids and terpenes.

Placebo

Participants will be administered a placebo

Primary outcome measure

  • Depression Monthly Assessment: Center for Epidemiologic Studies Depression Scale (CES-D) [ Time Frame: The survey will be completed shortly after the monthly Zoom sessions, during four different sessions. They will occur at approximately week 1, 5, 9, and 13. ]
  • Anxiety Monthly Assessment: Beck Anxiety Inventory [ Time Frame: The survey will be completed shortly after the monthly Zoom sessions, during four different sessions. They will occur at approximately week 1, 5, 9, and 13. ]
  • Perimenopausal Depression Monthly Assessment: Meno-D [ Time Frame: The survey will be completed shortly after the monthly Zoom sessions, during four different sessions. They will occur at approximately week 1, 5, 9, and 13. ]
  • Emotional/Mental Symptoms Daily Assessment [ Time Frame: Emotional/mental symptoms will be assessed during each session (morning and night) of the daily EMA assessments, for the 3 month duration of the study. ]

Central Contacts and Locations

Central contacts

Carrie Cuttler, PhD

(509) 592-0151carrie.cuttler@wsu.edu

Locations

Washington State University, Dept of Psychology

Recruiting

Pullman, Washington, United States, 99164

Contacts

Carrie Cuttler, PhD

509-592-0151carrie.cuttler@wsu.edu

Principal Investigator:

Carrie Cuttler, PhD

More Information

Sponsor

Washington State University

Last update posted

Mar 10, 2026

Last verified

Mar, 2026

Keywords

  • Menopause
  • Perimenopause
  • Cannabinoids
  • CBG
  • CBD
  • Hemp-derived THC
  • Cognition
  • Anxiety
  • Sleep
  • Mood
  • Pain
  • Stress
  • Brain fog

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Washington State University on 2026-03-10.